An interventional study of RapidPulseTM Aspiration System in Acute Ischemic Stroke, sponsored by RapidPulse, Inc. Recruiting at 30 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by RapidPulse, Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.
Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 113th largest by planned enrollment of the 364 interventional ones that give a count, is one of 24 that started in 2025, is one of 183 with no phase, reaches primary completion later than 60 of the 144 other live ones, and was the 385th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18+
Casa Colina Hospital and Centers for Healthcare · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 40+
Magnetic Tides · Sites in United States
Ages 18–80
Vanderbilt University Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
480 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 103 · Phase 3 46 · Phase 4 11
First in 1993; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 65 across the 364 interventional studies, 300 across the 111 observational. Of the 283 that completed or were terminated, 129 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 480 have an industry lead sponsor. The 10 most frequent:
RapidPulse, Inc is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
RapidPulse, Inc has 4 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
49 of the studies in Ischemic Stroke with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07649135University of MinnesotaFeasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke | 2026-11-30 |
| NCT05085210Beth Israel Deaconess Medical CenterImproving Visual Field Deficits With Noninvasive Brain Stimulation | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 480 studies in Ischemic Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.
The purpose of this prospective, open label clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System as frontline approach in the treatment of large vessel occlusions in patients experiencing Acute Ischemic Stroke within 8 hours of symptom onset or last seen normal. The target sample size for this clinical trial is 170 subjects enrolled in up to 40 sites globally. The maximum number of subjects that may be enrolled is 340. Subjects will undergo mechanical thrombectomy procedure and will have postoperative assessments completed at 24 hours and on day 5-7 or hospital discharge (whichever comes first). The final study visit will occur approximately 90 days after the index event. The primary effectiveness endpoint is the proportion of patients who achieve modified treatment in cerebral infarction score (mTICI) ≥ 2b, based on the best mTICI score within a maximum of 3 passes where only aspiration with the Study Device was used without rescue, as assessed by an independent Imaging Core Lab. The primary safety endpoint is the proportion of patients with symptomatic ICH (sICH) at 24 hours post-thrombectomy as assessed by an independent central events committee (CEC).
The criteria were revised on the registry on Oct 21, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove the thrombus in the neuro-vasculature using the RapidPulseTM Aspiration System.
Device: RapidPulseTM Aspiration System
The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulseTM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.
Also known as: Aspiration Thrombectomy, Thrombectomy
Rate of perfusion success using only the study device.
The proportion of patients who achieve mTICI ≥ 2b within a maximum of 3 passes where only aspiration with the Study Device was used without rescue, as assessed by an independent Imaging Core Lab.
Time frame: Intra-procedural
Rate of symptomatic intracranial hemorrhage (sICH)
The proportion of patients with symptomatic ICH (sICH) at 24 hours post-thrombectomy
Time frame: Post-procedural (24 hours post-thrombectomy)
Modified Rankin Scale (mRS) at 90 days post treatment
Proportion of patients who achieve mRS ≤2 at 90-days post treatment.
Time frame: Post-procedure (90 days post-thrombectomy)
Rate of modified First Pass Reperfusion Effect (mFPE) after one reperfusion attempt
Modified First Pass Reperfusion Effect (mFPE) as defined by mTICI ≥ 2c after one device pass
Time frame: Intra-procedural
Rate of modified First Pass Reperfusion Effect (mFPE) after one reperfusion attempt
Modified First Pass Reperfusion Effect (mFPE) as defined by mTICI ≥ 2b after one device pass
Time frame: Intra-procedural
Final reperfusion effect
Final mTICI ≥ 2b after all passes (including any rescue therapy) at procedure conclusion
Time frame: Intra-procedural
Time to reperfusion
Time from arterial puncture (procedure initiation) to achieve mTICI ≥ 2b using first line aspiration treatment.
Time frame: Intra-procedural
Rate of major early neurological recovery
Proportion of patients with major early neurological recovery at 24-hours as defined by reduction in National Institutes of Health Stroke Scale (NIHSS) score from baseline of at least 8 points or reaching NIHSS 0-1. \*NIHSS ranges from 0 to 42, with higher scores indicating greater neurological deficit.
Time frame: Post-procedure (24 hours post-thrombectomy)
Rate of major early neurological recovery
Change in NIHSS score from Baseline to 24 hours
Time frame: 24 hours
Incidence of Adverse Events (AEs)
All recorded adverse events as assessed by the independent CEC.
Time frame: Intra-procedural to post-procedure (through 90 days post-thrombectomy)
Incidence of Serious Adverse Events (SAEs)
All device-related and procedure-related serious adverse events as assessed by the independent CEC.
Time frame: Intra-procedural to post-procedure (through 90 days post-thrombectomy)
Incidence of all cause mortality
All-cause mortality assessed through 90 days post index procedure.
Time frame: Intra-procedural to post-procedure (through 90 days post-thrombectomy)
Incidence of device related vasospasm
Device-related vasospasm
Time frame: Intra-procedural
Incidence of embolism in new territory
Embolism in new territory determined based on procedural angiogram
Time frame: Intra-procedural
Incidence of all intracranial hemorrhage
Any intracranial hemorrhage according to the Heidelberg classification at 24-hours
Time frame: Post-procedural (24 hours post-thrombectomy)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jun 2027, 27 months after the start.
Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 27 months is above that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jan 2027 → Jun 2027 and completion Apr 2027 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RapidPulse, Inc